OLMA - NASDAQ
Olema Pharmaceuticals, Inc.
$10.51
-1.7%Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
At a Glance
Live SnapshotOlema Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Olema Pharmaceuticals, Inc. Cash Flow Statement
OLMA • NASDAQ
| Olema Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-162.5M | -129.5M | -96.7M | -104.8M | -71.1M | -22.1M | -4.3M | -2.2M | |
490K | 393K | 377K | 1.7M | 1.7M | 11K | 9K | 8K | |
17.6M | 22.6M | 17.3M | 0.0 | 0.0 | 3.1M | 0.0 | 1K | |
-5.1M | -7M | -4.1M | 18M | 15.9M | 641K | -1.1M | 122K | |
2.8M | 9.2M | -589K | 3M | 2.8M | -1.5M | 1.2M | -110K | |
-146.7M | -104.4M | -83.7M | -82.1M | -50.7M | -19.9M | -3.1M | -2.2M | |
INVESTING ACTIVITIES | ||||||||
(0.0) | -159K | (0.0) | -363K | -1.6M | -56K | (0.0) | (0.0) | |
-500.7M | -395M | -255.6M | -213.7M | -487M | (0.0) | (0.0) | (0.0) | |
345M | 301.6M | 250.8M | 305.5M | 213.1M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 14K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-155.8M | -93.5M | -4.9M | (91.5M) | -275.4M | -56K | (0.0) | (0.0) | |
FINANCING ACTIVITIES | ||||||||
208.3M | 266.3M | 129.7M | 476K | 1.4M | 355.3M | 0.0 | 0.0 | |
3M | 0.0 | 0.0 | 0.0 | 0.0 | 3.1M | 0.0 | 323K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -2.3M | (0.0) | (0.0) | |
0.0 | 2.5M | 3.7M | 0.0 | 0.0 | 0.0 | 0.0 | 4.9M | |
211.3M | 268.8M | 133.4M | 476K | 1.4M | 358.4M | 0.0 | 5.3M | |
CASH FLOW SUMMARY | ||||||||
-91.2M | 70.9M | 44.8M | 9.9M | -324.7M | 338.5M | -3.1M | 3.1M | |
139.5M | 68.5M | 23.7M | 13.8M | 338.5M | 68K | 3.1M | 71K | |
48.3M | 139.5M | 68.5M | 23.7M | 13.8M | 338.5M | 68K | 3.1M | |
-146.7M | -104.5M | -83.7M | -82.4M | -52.3M | -19.9M | -3.1M | -2.2M |
SEC Filings
OLMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 16, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 27, 2026 | 2026 |
Related Guides
Continue your OLMA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.